TMCnet News
Biophan Technologies CEO Michael Weiner Gives Internet Broadcast Interview to CEOcast ROCHESTER, N.Y. --(Business Wire)-- Nov. 8, 2004 -- Biophan Chief Discusses Company's Next-Generation Technology and Products in MRI Safety, Drug-Elution, and Other AreasBiophan Technologies Inc., (OTC BB:BIPH), a developer of next-generation biomedical technology, announced that Company CEO Michael Weiner has given an online interview on Nov. 5 to CEOcast, a wide-reaching online community of investors and investment professionals. In the interview, located at www.ceocast.com, Mr. Weiner discussed Biophan's overall business initiatives, including the Company's product and technology initiatives for biomedical markets, such as enhancement of Magnetic Resonance Imaging, drug-elution, nanotechnology, and thermoelectric battery technology for implantable medical devices. Mr. Weiner discussed recent Company milestones and events, and provided insight into Biophan's plans for increasing revenue and shareholder value through release of new products and technologies. He described various patents, products, and technologies under development at Biophan, such as the Company's latest advances in nanotechnology solutions that enable enhanced MRI safety and effectiveness. The streaming audio interview is available free of charge to visitors at www.ceocast.com. "I appreciate the opportunity CEOcast has given me to address investors interested in hearing Biophan's story," said Mr. Weiner. "The CEOcast website reaches a significant number of investors and industry professionals, and thus is an excellent platform to assist us in getting accurate and timely information about Biophan out to the investment community." About CEOcast CEOcast is the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street's leading companies. CEOcast's programming is distributed to on-line investors at over numerous financial web sites as well as to many portfolio managers, buy-side analysts and traders at North American institutions. Content is also disseminated to investment research professionals representing a substantial number of institutions. About Biophan Technologies Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
